China Pharma Holdings: Taiwan's TCM Pavilion Shines at CPHI Frankfurt 2025

### Taiwan's Traditional Chinese Medicine Pavilion Makes a Splash at CPHI Frankfurt 2025

The Taiwan Traditional Chinese Medicine (TCM) Pavilion marks a significant milestone for Taiwan's health sector, showcasing the nation’s commitment to integrating traditional medicine with modern scientific advancements. Organized by the Taiwan Institute of Economic Research and supported by the Department of Chinese Medicine and Pharmacy, this inaugural pavilion at CPHI Frankfurt 2025 draws considerable attention from healthcare professionals, pharmaceutical experts, and international distributors. The event, held from October 28 to 30, serves as a launchpad for Taiwan's first national TCM pavilion, emphasizing the island's dedication to evidence-based TCM practices and its burgeoning research and development capabilities.

The pavilion hosts 121 professional visitors and facilitates four business matchmaking sessions with five international companies and two business and investment organizations, signaling strong interest in potential collaborations. This engagement not only underscores the global appeal of Taiwan's TCM but also reflects a growing trend among countries to embrace traditional medicine within the framework of modern healthcare. Key figures like Mr. Mei-Shun Lo and Bertram Roth express optimism about future cooperation, reinforcing the strategic importance of TCM in fostering international health partnerships. This event highlights Taiwan's proactive approach in promoting its traditional medicine on a global scale, aiming to create new opportunities and enhance its international standing in the healthcare sector.

The success of the Taiwan TCM Pavilion at CPHI Frankfurt illustrates a broader movement toward integrating traditional practices with scientific validation. By showcasing its advancements, Taiwan sets an example for how traditional medicine can coexist with modern healthcare paradigms, fostering an environment of innovation and collaboration. The meaningful exchanges that happen at this event pave the way for further advancements in the integration of traditional and contemporary medical practices, potentially leading to groundbreaking developments in both sectors.

In related developments, IDT Biologika GmbH, the European arm of SK bioscience, is expanding its global contract development and manufacturing (CDMO) operations for vaccines and biopharmaceuticals. The company emphasizes its end-to-end manufacturing capabilities and engagement at major industry events, including CPHI Frankfurt 2025, which aligns with the trends in the biopharmaceutical sector towards increased customization and flexibility in production.

With a focus on scalable CDMO platforms, IDT positions itself as a significant player in the vaccine and biopharmaceutical markets, which complements Taiwan's initiatives in TCM. Both Taiwan and IDT highlight the importance of innovation in healthcare, suggesting that traditional and modern practices can converge to enhance patient care and treatment options globally.